In brief: Eqitx, Stirling Products
Monday, 12 July, 2004
Two Perth-based biotechs have made key executive appointments.
Drug development company Eqitx (ASX:EQX) has former CSL and Amrad business development executive Joy Hewitt as its chief commercialisation officer.
At CSL, Hewitt was R&D and pharmaceuticals business development manager, where her responsibilities included commercialising CSL projects, evaluating and securing R&D opportunities, and in-licensing pharmaceutical products for domestic and NZ markets. Eqitx said Hewitt had also acted as a consultant to Australian research, biotech and medical organisations.
Animal growth promoter specialist Stirling Products (ASX:STI) has appointed Murray Ward, a stockbroker with 20 years' experience, as an executive director.
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
